USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
GERINDA THERAPEUTICS, INC
Address:
1001 SHELDON DR
CARY, NC 27513-2012
Phone:
N/A
URL:
N/A
EIN:
126151527
DUNS:
9695452
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $248,481.00 1

Award List:

New ultra-selective kinase inhibitors for the treatment of AML

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$248,481.00
Agency:
HHS
Principal Investigator:
Magnus P. Pfahl – 858-646-0706
Abstract:
DESCRIPTION (provided by applicant): Acute Myeloid Leukemia (AML) accounts for a high percentage of all adult leukemia cases. Although most patients at first respond well to conventional chemotherapy, there is a high rate of relapse and patients become refractory to front-line treatment, which bears… More